Mirion Technologies

Mirion Technologies, Inc. engages in the provision of nuclear measurement and detection systems. It offers measurement and enterprise, calibration, customer training programs, installation, product support and repairs, consulting, and instadose desimetry services. The company was founded by Thomas D. Logan in December 2005 and is headquartered in Atlanta, GA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Mirion Technologies posts robust Q4 earnings, eyes SMR market growth

Mirion Technologies reported strong financials, with double-digit revenue growth and a focus on reducing leverage, despite challenges like supply chain issues.
The company's strategic focus on the Medical and Industrial segments, along with opportunities in the SMR market, bode well for future growth.
Balanced growth strategies, disciplined capital allocation, and engagement in key markets position Mirion Technologies for continued success in 2023.

Mirion Technologies reports robust Q1 earnings, eyes growth opportunities

Mirion Technologies delivered strong Q1 results, focusing on operational efficiency, margin improvement, and cash flow generation. The company's rebranding efforts and positive market outlook position it well for future growth. With a history of margin expansion and free cash flow conversion, Mirion is poised for continued success in 2023.

Mirion Technologies posts robust Q2 results and eyes growth opportunities

Mirion Technologies delivered strong Q2 results with positive revenue growth and operational performance.
The company's focus on margin improvement and order intake positions it well for future success.
Despite challenges in pricing dynamics and cash flow, Mirion Technologies remains optimistic about its outlook.

Mirion Technologies excels in Q3 with strong order growth and record backlog

Mirion Technologies delivered a strong Q3 performance with significant order growth and record backlog, supported by strategic acquisitions and operational focus.
While facing challenges in organic growth and margin maintenance, the company remains optimistic about future opportunities for revenue expansion and profitability.
Maintaining financial targets, optimizing cash flow, and emphasizing margin expansion are key priorities for sustained success and market leadership.

Mirion Technologies reports record 2023 results and bullish 2024 guidance

Mirion Technologies had a stellar 2023, setting records in revenue, EBITDA, and free cash flow, with strong guidance for 2024.
The company is strategically focused on margin expansion, cost control, and product innovation to drive future growth.
While facing challenges in healthcare reimbursement and cost management, Mirion is leveraging international markets and new product introductions.
Confidence in achieving growth targets, Mirion remains committed to operational excellence and enhancing shareholder value.

Mirion Technologies reports solid Q1 performance, eyes growth opportunities

Mirion Technologies demonstrated strong financial performance in Q1 2024, driven by key growth drivers in nuclear power and cancer care. Despite challenges in cash flow and margin pressure, the company remains focused on growth opportunities through innovation and strategic initiatives.

Mirion Technologies reports solid Q2 results, eyes growth opportunities

Mirion Technologies showcased solid performance with margin exceeding expectations and raised EBITDA guidance. While facing tough order growth comps, the company is focused on driving organic growth and improving cost structure. Anticipated improvements in Chinese market dynamics and potential positive impact from upcoming CMS changes present growth opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Mirion Technologies, Inc. engages in the provision of radiation safety, science, and medicine. It operates through the Medical and Technologies segments. The Medical segment consists of sales, products, and services to customers in the medical market. The Technologies segment involves nuclear energy, defense, laboratories, and scientific research markets as well as other industrial markets. The company was founded by Thomas D. Logan in December 2005 and is headquartered in Atlanta, GA.

ATLANTA--(BUSINESS WIRE)--Mirion ("we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the first quarter ended March 31, 2023. During the first quarter, Mirion received a $150 million direct at-the-market investment and utilized $125 million for debt repayment. This helped the company bring net leverage down during the quarter. The compa.

Mirion Announces First Quarter 2023 Financial Results and Reaffirms Full Year Guidance

ATLANTA--(BUSINESS WIRE)--Mirion (“we” or “the company”(NYSE: MIR), a leading provider of advanced radiation safety solutions, today announced that it has updated the company's corporate branding and the branding of its Industrial segment. The overall corporate entity will now be branded as simply “Mirion”, with the Industrial segment taking the name “Mirion Technologies”. The company has also completed the launch of an enhanced website representing its comprehensive portfolio of products that.

Mirion Launches New Branding, Reflecting Comprehensive Solutions and Services Across Science, Industry and Medicine

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (NYSE: MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at Goldman Sachs' Industrials & Materials Conference in New York, NY. The presentation will begin at 9:20 AM ET on Tuesday, May 9, 2023. The presentation will be webcast live at https://ir.mirion.com/news-events where a link will be displayed under the "Events and Presentations” section. An archive of the webcas.

Mirion Technologies to Present at Goldman Sachs' Industrials & Materials Conference

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”) (“Company”) announced today that it will release its financial results for the first quarter of 2023 on Wednesday, May 3, 2023. Following the news release, the Company will host a conference call the same day at 12:00 pm ET to discuss the results. Participants may access the call by calling 1-877-407-9208 or 1-201-493-6784, and requesting to join the Mirion Technologies, Inc. earnings call.

Mirion Technologies Announces Earnings Release and Conference Call Date for First Quarter 2023

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced that it has agreed to sell $150 million of shares of Class A common stock to certain funds and accounts advised by T. Rowe Price Investment Management, Inc. (“T. Rowe Price”), a global investment management organization. T.

Mirion Technologies Announces $150 Million Investment from T. Rowe Price, Priced At-the-Market

NEW YORK--(BUSINESS WIRE)---- $MIR #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of GS Acquisition Holdings Corp II, which merged with Mirion Technologies, Inc. ("Mirion" or "the Company") (NYSE: MIR) on October 20, 2021. Such investors who continue to hold to the present are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/mir.

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Mirion Technologies, Inc. (MIR) Investigation

Mirion Technologies, Inc. (NYSE:MIR ) Q4 2022 Earnings Conference Call February 14, 2023 10:00 AM ET Company Participants Alex Gaddy - Vice President, Head, Strategy and Corporate Development Larry Kingsley - Chairman of the Board Tom Logan - Chief Executive Officer Brian Schopfer - Chief Financial Officer Conference Call Participants Andy Kaplowitz - Citigroup Joe Ritchie - Goldman Sachs Chris Moore - CJS Securities Operator Greetings. And welcome to Mirion Technologies Fourth Quarter 2022 Earnings Conference Call.

Mirion Technologies, Inc. (MIR) Q4 2022 Earnings Call Transcript

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the fourth quarter and fiscal year ended December 31, 2022. Mirion reported full year order growth for 2022 of approximately 8% compared to 2021. Backlog was $737.

Mirion Technologies Announces Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Fiscal Year 2023 Financial Guidance

Mirion Technologies to Present at Citi's 2023 Global Industrial Tech and Mobility Conference

ATLANTA--( BUSINESS WIRE )--Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”) (“Company”) announced today that it will release its financial results for the fourth quarter and fiscal year 2022 on Tuesday, February 14, 2023. Following the news release, the Company will host a conference call the same day at 10:00 am ET to discuss the results.

Mirion Technologies Announces Earnings Release and Conference Call Date for Fourth Quarter and Fiscal Year 2022 Results

Designation Recognizes Partnership for Improved Quality Management  and Enhanced Patient Care in Radiation Therapy MELBOURNE, Fla. , Jan. 26, 2023 /PRNewswire/ -- Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), announced today that it has designated Scripps Health as a Patient Safety Center of Excellence.

Scripps Health Radiation Therapy Centers Named Patient Safety Center of Excellence by Sun Nuclear

ATLANTA--( BUSINESS WIRE )--Mirion Technologies, Inc. (NYSE: MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at the CJS Securities 23rd Annual New Ideas for the New Year Conference. The presentation will begin at 3:45 PM ET on Wednesday, January 11, 2023.

Mirion Technologies to Present at the CJS Securities 23rd Annual New Ideas for the New Year Conference

ATLANTA--( BUSINESS WIRE )--Mirion Technologies, Inc. (NYSE: MIR) announced today that it has entered into a definitive agreement to sell the physical medicine assets of Biodex Medical Systems, Inc. (“Biodex”) to Salona Global Medical Device Corporation for $5 million in cash at closing and up to an additional $3 million in deferred cash payments. The deferred cash payments are contingent on the performance of the assets during the 12-month period following closing. The assets generated approximately $18 million in revenue with estimated gross margins of 30% during the most recent trailing twelve-month period.

Mirion Technologies to Divest Biodex Physical Medicine

SAN DIEGO, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Salona Global Medical Device Corporation (“Salona Global,” “SGMD,” or the “Company”) (TSXV:SGMD) has executed a definitive asset purchase agreement (the “Asset Purchase Agreement”) to acquire the physical medicine assets (the “Acquired Assets”) of Biodex Medical Systems, Inc. (“Biodex”). As part of the acquisition, at the closing the parties will execute a two-year contract manufacturing agreement (the “Supply Agreement”) with Biodex, which together with the Acquired Assets are expected to generate $26 million annually. The trailing 12-month revenues for the Acquired Assets were $18 million with gross margins of approximately 30%. The Supply Agreement is expected to generate 15% gross margins. Between cash, assets on the balance sheet and its existing debt facility the Company has sufficient funds to close the acquisition.

Salona Global Executes Binding Agreement to Acquire the Physical Medicine Assets of Biodex Medical Systems, Inc.

Mirion Technologies, Inc. (NYSE:MIR ) Q3 2022 Results Conference Call November 1, 2022 4:30 PM ET Company Participants Alex Gaddy - VP, Head of Strategy & Corporate Development Larry Kingsley - Chairman of the Board Tom Logan - Chief Executive Officer Brian Schopfer - Chief Financial Officer Conference Call Participants Joe Ritchie - Goldman Sachs Chris Moore - CJS Securities Andy Kaplowitz - Citigroup Operator Greetings. And welcome to Mirion Technologies Inc. Third Quarter 2022 Earnings Conference Call.

Mirion Technologies, Inc. (MIR) Q3 2022 Earnings Call Transcript

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion,” "we" or the "company") (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced results for the third quarter ended September 30, 2022.

Mirion Technologies Announces Third Quarter 2022 Financial Results

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (NYSE: MIR) announced today that Chief Executive Officer, Thomas Logan, and Chief Financial Officer, Brian Schopfer, will present at the 2022 Baird Industrial Conference in Chicago, IL.

Mirion Technologies to Present at the 2022 Baird Industrial Conference

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (NYSE: MIR) (“Mirion”) (“Company”) announced today that it will release its financial results for the third quarter of 2022 on Tuesday, November 1, 2022 after the market closes.

Mirion Technologies Announces Earnings Release and Conference Call Date for Third Quarter 2022

Featuring Automated In-Vivo QA, SRS-Class Dosimetry, Motion QA, and More MELBOURNE, Fla. , Oct. 21, 2022 /PRNewswire/ -- Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), will present its comprehensive Quality Management portfolio, with expanded offerings from CIRS, now part of Sun Nuclear, at the ASTRO Annual Meeting, October 23-25, 2022, in San Antonio, Texas.

Expanded Portfolio for Better Quality Management from Sun Nuclear at the 2022 ASTRO Annual Meeting

Initial Innovations to be Featured at 2022 ASTRO Annual Meeting  MELBOURNE, Fla. , Oct. 19, 2022 /PRNewswire/ -- Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced that it is developing new Quality Management solutions, in collaboration with Accuray, for the company's Radixact® System with Synchrony®, which enables real-time, personalized adaptive radiation therapy.

Sun Nuclear Partners with Accuray to Develop New Quality Management Solutions for the Radixact® System with Synchrony®

It is highly doubtful that a clean energy revolution can take place without nuclear energy playing a vital role. An investor can be exposed to the upside by owning the metal or a miner or a business that sustains this industry.

Mirion Technologies: A Smart Way To Be Bullish On Clean Energy

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced the appointment of Michael Rossi as the President of Mirion Medical. Michael will report directly to Mirion's CEO, Tom Logan, who had been acting as President of the business segment. Michael joins Mirion from Novartis, where he most r

Mirion Technologies Appoints Michael Rossi as President of Mirion Medical

Key Information Security Certification Extends to SunCHECK® Platform for Quality Management in Radiation Therapy   MELBOURNE, Fla. , Sept. 22, 2022 /PRNewswire/ -- Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced that it has achieved ISO/IEC 27001:2013 certification for its information security management system (ISMS).

Sun Nuclear Awarded ISO/IEC 27001:2013 Certification

ATLANTA--(BUSINESS WIRE)--Mirion Technologies, Inc. (“Mirion,” “we” or the “Company”) (NYSE: MIR), a global provider of radiation detection, measurement, analysis and monitoring solutions to the medical, nuclear, defense, and research end markets, today announced that Dr. Sheila Rege, M.D. has been appointed to the Board of Directors, replacing Mr. Christopher Warren, who is stepping down. Lawrence D. Kingsley, Chairman of Mirion's Board of Directors said, “I am pleased to welcome Sheila to Mir

Mirion Technologies Appoints Dr. Sheila Rege, M.D. to Board of Directors, Replacing Mr.

Custom ATOM® Phantoms to Represent Astronauts on Historic Uncrewed Mission  MELBOURNE, Fla. , Aug. 25, 2022 /PRNewswire/ -- Sun Nuclear, a wholly-owned subsidiary of Mirion Technologies, Inc. (NYSE: MIR) ("Mirion"), today announced its ATOM® Phantom product line will play a vital role in the first of a series of NASA missions aimed at enabling human exploration to the Moon and Mars.

News for Mirion Technologies Stock (MIR)